KBank and Ant International Partner on Cross-Border Payments and Liquidity Management in Thailand
29.5.2026 05:00:00 CEST | Business Wire | Press Release
KASIKORNBANK (KBank) and Ant International have formed a strategic collaboration to jointly develop an integrated financial infrastructure to deliver faster, more reliable, and scalable payment experiences for Ant International and its customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528577525/en/
Kelvin Li, General Manager of Platform Tech and Senior Vice President at Ant International (Left) and Dr. Karin Boonlertvanich, Executive Vice President of KASIKORNBANK (Right) at the MOU Signing Ceremony
The Memorandum of Understanding (MoU) will combine KBank’s regulated financial capabilities with Ant International’s financial AI solutions to enable real-time, 24/71 cross-border USD transactions. The initiative will leverage Blockchain Deposit Accounts from Kinexys by J.P. Morgan, the industry-leading blockchain business part of J.P. Morgan Payments for real-time USD liquidity movement and is expected to significantly enhance transaction speed while enabling continuous 24/72 operations. KBank and Ant International will also use their best efforts to develop end-to-end solutions across payment acceptance, clearing, and settlement. These advancements remain subject to all necessary legal and regulatory approvals.
This collaboration will enhance Ant International’s inbound and outbound transaction and settlement efficiency, thus improving the business cashflow of the merchants the company serves.
This partnership builds on KBank’s existing collaboration with Ant International’s global payment services. Through Alipay+, Ant International’s digital wallet gateway, KBank’s mobile banking app KPLUS is connected into an ecosystem of 150 million merchants and 1.8 billion consumer accounts worldwide. KPLUS is also a growing payment option on Google Pay for Thai merchants through its integration with Antom, Ant International’s merchant payment service.
Dr. Karin Boonlertvanich, Executive Vice President of KASIKORNBANK, said, “This collaboration addresses a fundamental limitation in today’s cross-border financial systems, where liquidity movement remains constrained by fragmented infrastructure. By integrating blockchain with regulated financial systems, we are enabling a more continuous, transparent, and scalable flow of funds between global networks and local economies.”
Kelvin Li, General Manager of Platform Tech and Senior Vice President at Ant International, said, “Across emerging markets, industry leaders like KBank are preparing communities for a more interconnected global economy with broader and more secure application of AI and blockchain technology. We are thrilled to support KBank with such fintech solutions to empower Thai merchants – especially small businesses – with more efficient payment tools to thrive globally.”
This MOU underscores a shared commitment to the development of integrated and scalable cross-border financial systems, enhancing the efficiency and reliability of global payment systems for international commerce.
The development and potential implementation of this initiative will be undertaken in consultation with the relevant regulatory authorities, and will be subject to obtaining the necessary approvals prior to any live service deployment.
About KASIKORNBANK
KASIKORNBANK PUBLIC COMPANY LIMITED (KBank) operates under the vision of being a “Bank of Sustainability”, dedicated to delivering long-term value to all stakeholders through innovation, strong governance, and responsible growth. KBank continues to strengthen its leadership in digital banking through strategic initiatives that drive financial inclusion and cross-border interoperability, including the development of blockchain-based infrastructure and regulated on-chain payment ecosystems in partnership with global innovators.
About Ant International
Ant International is a leading global digital payment, digitisation and financial technology provider. Through collaboration across the private and public sectors, our unified techfin platform supports financial institutions and merchants of all sizes to achieve inclusive growth through a comprehensive range of cutting-edge digital payment and financial services solutions. To learn more, please visit https://www.ant-intl.com/
| 1 Transfers on the network are completed on a 24/7/365 and same day basis. Moving funds to and from the network from traditional Demand Deposit Accounts on legacy systems to Blockchain Deposit Accounts has a three- hour downtime over the weekend (3-6 p.m. EST every Saturday.) Enhancement is under development. | |
| 2 Transfers on the network are completed on a 24/7/365 and same day basis. Moving funds to and from the network from traditional Demand Deposit Accounts on legacy systems to Blockchain Deposit Accounts has a three- hour downtime over the weekend (3-6 p.m. EST every Saturday.) Enhancement is under development. | |
View source version on businesswire.com: https://www.businesswire.com/news/home/20260528577525/en/
Contacts
Media Contact
KASIKORNBANK
kbankpr@kasikornbank.com
Ant International
Global Communications
pr@ant-intl.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press Release
OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press Release
Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press Release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press Release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, strategy, and business transformation. She most recently served as Global Head of Deloitte Digital and previously held senior global leadership roles,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom